US2020390744A1PendingUtilityA1

Treatment of androgen deprivation therapy associated symptoms

56
Assignee: LILLY CO ELIPriority: Sep 11, 2014Filed: Aug 26, 2020Published: Dec 17, 2020
Est. expirySep 11, 2034(~8.1 yrs left)· nominal 20-yr term from priority
Inventors:Charles T. BensonRachel Nicole RicheyHannah Yu
A61K 31/4439A61K 31/403C07D 401/06A61P 35/00A61P 21/00A61P 19/00A61P 15/08A61P 5/26A61K 31/405A61P 13/08A61P 19/08A61P 43/00C07D 209/94C07D 209/60A61P 15/10C07D 209/58A61P 21/06
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a method of treating symptoms associated with Androgen Deprivation Therapy comprising administering to a patient in need of such treatment an effective amount of a compound of Formula I: or a pharmaceutically acceptable salt thereof.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A pharmaceutical composition comprising a substantially pure form of (S)-(7-cyano-4-pyridin-2-ylmethyl-1,2,3,4-tetrahydro-cyclopenta[b]indol-2-yl)-carbamic acid isopropyl ester or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The pharmaceutical composition form according to  claim 1 , wherein the composition comprises less than 15% by weight of impurities. 
     
     
         3 . The pharmaceutical composition form according to  claim 1 , for the treatment of the symptoms of secondary hypogonadism induced by androgen deprivation therapy. 
     
     
         4 . The pharmaceutical composition according to  claim 1 , wherein said pharmaceutical composition is in the form of a capsule. 
     
     
         5 . A technical grade form of (S)-(7-cyano-4-pyridin-2-ylmethyl-1,2,3,4-tetrahydro-cyclopenta[b]indol-2-yl)-carbamic acid isopropyl ester or a pharmaceutically acceptable salt thereof.

Join the waitlist — get patent alerts

Track US2020390744A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.